| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
9-Fluorenylmethanol is used as an N-protecting reagent in peptide synthesis. Its target is the amino group of amino acids or peptides. Its mechanism of action involves the formation of a carbamate linkage that protects the amino group from unwanted reactions during peptide synthesis. The fluorenylmethyl group can be removed under mild basic conditions (e.g., with piperidine), allowing for selective deprotection of the amino group. This protecting group strategy is widely used in solid-phase peptide synthesis (SPPS).
|
|---|---|
| ln Vitro |
In vitro, 9-Fluorenylmethanol is used as an N-protecting reagent in peptide synthesis. It is also used in the design and synthesis of novel somatostatin analogs with antiproliferative activities on A431 tumor cells. The compound's role in peptide synthesis is to protect the amino group of amino acids during the stepwise assembly of peptides. Its use enables the synthesis of complex peptides and peptide analogs for research and drug development.
|
| ln Vivo |
In vivo activity of 9-Fluorenylmethanol is not studied, as it is a reagent for peptide synthesis rather than a bioactive drug. However, peptides synthesized using this protecting group may have in vivo activities. The compound itself is not intended for administration to animals or humans. Its role is limited to the in vitro synthesis of peptides.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays using 9-Fluorenylmethanol are not typical, as it is a protecting group reagent. However, its use in peptide synthesis enables the production of peptides that can be used in various assays. A standard protocol for peptide synthesis using Fmoc chemistry: the amino acid with its amino group protected by the fluorenylmethyl group (Fmoc-amino acid) is coupled to a resin-bound peptide chain. After coupling, the Fmoc group is removed with piperidine to expose the free amino group for the next coupling cycle. This cycle is repeated until the desired peptide sequence is assembled. The peptide is then cleaved from the resin and deprotected.
|
| Cell Assay |
In vitro cell-based assays for 9-Fluorenylmethanol are not applicable, as it is not a cell-active compound. It is used in chemical synthesis, not in cell-based experiments. However, the peptides synthesized using this reagent can be tested in cell-based assays for their biological activities.
|
| Animal Protocol |
In vivo animal experiments for 9-Fluorenylmethanol are not performed, as it is a reagent for peptide synthesis and not a drug. It is not intended for administration to animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 9-Fluorenylmethanol are not relevant, as it is a reagent for peptide synthesis and not a drug. The compound is typically stored as a powder at room temperature. It is soluble in organic solvents such as dichloromethane, DMF, and DMSO. Its stability and reactivity are the main considerations for its use in peptide synthesis.
|
| Toxicity/Toxicokinetics |
Toxicity data for 9-Fluorenylmethanol is limited. As a chemical reagent, it should be handled with standard laboratory precautions. Inhalation, ingestion, and skin contact should be avoided. Appropriate personal protective equipment should be worn. The compound is not intended for human use.
|
| Additional Infomation |
9-Fluorenylmethanol is an N-protecting reagent useful in peptide synthesis. It is also known as 9-Fluorenemethanol. The compound is used in the design and synthesis of somatostatin analogs. It is not a drug and has no clinical use or approval status. It is commercially available from chemical suppliers for research purposes only.
|
| Molecular Formula |
C14H12O
|
|---|---|
| Molecular Weight |
196.2445
|
| Exact Mass |
196.088
|
| CAS # |
24324-17-2
|
| PubChem CID |
90466
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
363.9±11.0 °C at 760 mmHg
|
| Melting Point |
105-107 °C(lit.)
|
| Flash Point |
167.4±15.1 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.639
|
| LogP |
3.33
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
203
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C([H])([H])C1([H])C2=C([H])C([H])=C([H])C([H])=C2C2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
XXSCONYSQQLHTH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H12O/c15-9-14-12-7-3-1-5-10(12)11-6-2-4-8-13(11)14/h1-8,14-15H,9H2
|
| Chemical Name |
9H-fluoren-9-ylmethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~63.69 mM)
Ethanol : ~10 mg/mL (~50.96 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0958 mL | 25.4790 mL | 50.9580 mL | |
| 5 mM | 1.0192 mL | 5.0958 mL | 10.1916 mL | |
| 10 mM | 0.5096 mL | 2.5479 mL | 5.0958 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
